Cubist Systematic Strategies LLC Purchases 64,388 Shares of Inogen, Inc. (NASDAQ:INGN)

Cubist Systematic Strategies LLC raised its holdings in Inogen, Inc. (NASDAQ:INGN - Free Report) by 109.4% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 123,242 shares of the medical technology company's stock after acquiring an additional 64,388 shares during the quarter. Cubist Systematic Strategies LLC owned approximately 0.52% of Inogen worth $1,130,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD increased its position in Inogen by 5.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 26,710 shares of the medical technology company's stock valued at $245,000 after acquiring an additional 1,318 shares during the period. Invesco Ltd. increased its position in Inogen by 2.0% in the 4th quarter. Invesco Ltd. now owns 78,142 shares of the medical technology company's stock valued at $717,000 after acquiring an additional 1,545 shares during the period. Wells Fargo & Company MN increased its position in Inogen by 27.8% in the 4th quarter. Wells Fargo & Company MN now owns 13,917 shares of the medical technology company's stock valued at $128,000 after acquiring an additional 3,031 shares during the period. Bank of America Corp DE increased its position in Inogen by 2.7% in the 4th quarter. Bank of America Corp DE now owns 127,326 shares of the medical technology company's stock valued at $1,168,000 after acquiring an additional 3,304 shares during the period. Finally, AlphaQuest LLC acquired a new position in Inogen in the 4th quarter valued at approximately $43,000. 89.94% of the stock is currently owned by institutional investors and hedge funds.

Inogen Price Performance

Shares of INGN traded up $0.04 during trading hours on Monday, hitting $6.13. 239,015 shares of the stock were exchanged, compared to its average volume of 236,948. The firm has a market capitalization of $164.82 million, a P/E ratio of -2.72 and a beta of 1.63. Inogen, Inc. has a fifty-two week low of $5.70 and a fifty-two week high of $13.33. The business has a 50-day moving average of $6.95 and a 200-day moving average of $8.78.

Inogen (NASDAQ:INGN - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The medical technology company reported ($0.25) earnings per share for the quarter, beating analysts' consensus estimates of ($0.52) by $0.27. Inogen had a negative net margin of 15.89% and a negative return on equity of 27.38%. The firm had revenue of $82.28 million for the quarter, compared to analyst estimates of $79.57 million. As a group, analysts forecast that Inogen, Inc. will post -1.73 earnings per share for the current fiscal year.

Analysts Set New Price Targets

INGN has been the subject of several recent research reports. Needham & Company LLC restated a "hold" rating on shares of Inogen in a research report on Wednesday, April 9th. Stifel Nicolaus decreased their price objective on shares of Inogen from $10.00 to $7.00 and set a "hold" rating for the company in a research report on Thursday, May 8th. Finally, StockNews.com cut shares of Inogen from a "buy" rating to a "hold" rating in a research report on Wednesday, February 26th.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.